ERBB2 and neoplasm: The risk score calculated from the multi-locus signature and adjusted for tumour stage, age and AI treatment (ER+/HER2- cohort only) is significantly associated with survival (p < 10E-12) for all three cohorts (Additional File 8) indicating that DNA methylation is an independent factor in predicting survival.